Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC).

Ardizzoni, Andrea; Razis, Evangelia; Lichinitser, Mikhail; Yilmaz, Ugur; Grigorescu, Alexandru; Morero, Jusé Luis; Skřičková,  Jana; Cervantes, Guadalupe; Gottfried, Maya; Van Meerbeeck, Jan

Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC).

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	ARDIZZONI Andrea RAZIS Evangelia LICHINITSER Mikhail YILMAZ Ugur GRIGORESCU Alexandru MORERO Jusé Luis SKŘIČKOVÁ Jana CERVANTES Guadalupe GOTTFRIED Maya VAN MEERBEECK Jan
Year of publication	2007
Type	Article in Proceedings
Conference	Journal of Thoracic Oncology
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	Erlotinib; non-small cell lung cancer; drug safety; TRUST study
Description	An international group of authors have published interim results concerning the drug safety of erlotinib, an anti-tumor drug used in treatment of patients with advanced non-small cell lung cancer within TRUST, a global open-label study of erlotinib.
Related projects:	Environment - carcinogenesis - oncology